VERRICA PHARMACEUTICALS INC (VRCA) Stock Fundamental Analysis

NASDAQ:VRCA • US92511W2070

5.84 USD
+0.33 (+5.99%)
Last: Feb 18, 2026, 01:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall VRCA gets a fundamental rating of 2 out of 10. We evaluated VRCA against 191 industry peers in the Pharmaceuticals industry. VRCA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, VRCA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year VRCA has reported negative net income.
  • VRCA had a negative operating cash flow in the past year.
  • VRCA had negative earnings in each of the past 5 years.
  • VRCA had a negative operating cash flow in each of the past 5 years.
VRCA Yearly Net Income VS EBIT VS OCF VS FCFVRCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • VRCA's Return On Assets of -63.61% is on the low side compared to the rest of the industry. VRCA is outperformed by 68.06% of its industry peers.
Industry RankSector Rank
ROA -63.61%
ROE N/A
ROIC N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRCA Yearly ROA, ROE, ROICVRCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

  • VRCA has a Gross Margin of 91.36%. This is amongst the best in the industry. VRCA outperforms 93.19% of its industry peers.
  • VRCA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRCA Yearly Profit, Operating, Gross MarginsVRCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • VRCA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, VRCA has more shares outstanding
  • The debt/assets ratio for VRCA is higher compared to a year ago.
VRCA Yearly Shares OutstandingVRCA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
VRCA Yearly Total Debt VS Total AssetsVRCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • VRCA has an Altman-Z score of -10.28. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
  • VRCA has a Altman-Z score of -10.28. This is in the lower half of the industry: VRCA underperforms 69.63% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.28
ROIC/WACCN/A
WACC11.8%
VRCA Yearly LT Debt VS Equity VS FCFVRCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 1.25 indicates that VRCA should not have too much problems paying its short term obligations.
  • VRCA has a Current ratio of 1.25. This is in the lower half of the industry: VRCA underperforms 78.53% of its industry peers.
  • A Quick Ratio of 1.18 indicates that VRCA should not have too much problems paying its short term obligations.
  • VRCA has a worse Quick ratio (1.18) than 74.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.18
VRCA Yearly Current Assets VS Current LiabilitesVRCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • VRCA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.37%, which is quite impressive.
  • The Revenue has grown by 234.73% in the past year. This is a very strong growth!
  • Measured over the past years, VRCA shows a very negative growth in Revenue. The Revenue has been decreasing by -14.25% on average per year.
EPS 1Y (TTM)81.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.39%
Revenue 1Y (TTM)234.73%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%905.39%

3.2 Future

  • Based on estimates for the next years, VRCA will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.35% on average per year.
  • The Revenue is expected to grow by 83.00% on average over the next years. This is a very strong growth
EPS Next Y89.89%
EPS Next 2Y38.63%
EPS Next 3Y25.73%
EPS Next 5Y17.35%
Revenue Next Year324.96%
Revenue Next 2Y84.56%
Revenue Next 3Y90.54%
Revenue Next 5Y83%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRCA Yearly Revenue VS EstimatesVRCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
VRCA Yearly EPS VS EstimatesVRCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VRCA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRCA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRCA Price Earnings VS Forward Price EarningsVRCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRCA Per share dataVRCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VRCA's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.63%
EPS Next 3Y25.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VRCA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (2/18/2026, 1:05:09 PM)

5.84

+0.33 (+5.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)02-26
Inst Owners20.07%
Inst Owner Change74.33%
Ins Owners30.06%
Ins Owner Change11.79%
Market Cap93.38M
Revenue(TTM)30.83M
Net Income(TTM)-26.01M
Analysts81.82
Price Target16.83 (188.18%)
Short Float %4.46%
Short Ratio1.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)99.21%
Min EPS beat(2)95.64%
Max EPS beat(2)102.78%
EPS beat(4)3
Avg EPS beat(4)52.06%
Min EPS beat(4)-0.55%
Max EPS beat(4)102.78%
EPS beat(8)5
Avg EPS beat(8)23.1%
EPS beat(12)7
Avg EPS beat(12)14.8%
EPS beat(16)10
Avg EPS beat(16)22.31%
Revenue beat(2)2
Avg Revenue beat(2)166.29%
Min Revenue beat(2)140.71%
Max Revenue beat(2)191.87%
Revenue beat(4)3
Avg Revenue beat(4)74.63%
Min Revenue beat(4)-67.61%
Max Revenue beat(4)191.87%
Revenue beat(8)6
Avg Revenue beat(8)40.7%
Revenue beat(12)8
Avg Revenue beat(12)63.65%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-60.47%
EPS NY rev (1m)-13.93%
EPS NY rev (3m)-19.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-55.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.41
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-1.81
OCFYN/A
SpS1.93
BVpS-1.07
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.61%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.36%
FCFM N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.53%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.18
Altman-Z -10.28
F-Score4
WACC11.8%
ROIC/WACCN/A
Cap/Depr(3y)45.1%
Cap/Depr(5y)835.39%
Cap/Sales(3y)3.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.39%
EPS Next Y89.89%
EPS Next 2Y38.63%
EPS Next 3Y25.73%
EPS Next 5Y17.35%
Revenue 1Y (TTM)234.73%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%905.39%
Revenue Next Year324.96%
Revenue Next 2Y84.56%
Revenue Next 3Y90.54%
Revenue Next 5Y83%
EBIT growth 1Y78.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.2%
OCF growth 3YN/A
OCF growth 5YN/A

VERRICA PHARMACEUTICALS INC / VRCA FAQ

What is the ChartMill fundamental rating of VERRICA PHARMACEUTICALS INC (VRCA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VRCA.


Can you provide the valuation status for VERRICA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to VERRICA PHARMACEUTICALS INC (VRCA). This can be considered as Overvalued.


Can you provide the profitability details for VERRICA PHARMACEUTICALS INC?

VERRICA PHARMACEUTICALS INC (VRCA) has a profitability rating of 1 / 10.


How financially healthy is VERRICA PHARMACEUTICALS INC?

The financial health rating of VERRICA PHARMACEUTICALS INC (VRCA) is 1 / 10.